Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 20/20 | 0.61 |
| ▸ | JAK1 | P23458 | 4/20 | 0.61 |
| ▸ | JAK2 | O60674 | 3/20 | 0.61 |
| ▸ | JAK3 | P52333 | 3/20 | 0.61 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.60 |
| ▸ | RET | P07949 | 2/20 | 0.60 |
| ▸ | TYK2 | P29597 | 2/20 | 0.60 |
| ▸ | FLT3 | P36888 | 2/20 | 0.60 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.60 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.60 |
| ▸ | STK4 | Q13043 | 2/20 | 0.60 |
| ▸ | STK3 | Q13188 | 2/20 | 0.60 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 0.60 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.60 |
| ▸ | RPS6KA6 | Q9UK32 | 2/20 | 0.60 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.60 |
| ▸ | CSF1R | P07333 | 1/20 | 0.60 |
| ▸ | FLT4 | P35916 | 1/20 | 0.60 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.60 |
| ▸ | ITK | Q08881 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21455497 | 0.92 | SYK (0.63) | SYKJAK1JAK2JAK3CHEK1 | |
| SCHEMBL21455023 | 0.92 | SYK (0.65) | SYKJAK1JAK2JAK3CHEK1 | |
| SCHEMBL21455069 | 0.91 | SYK (0.73) | SYKJAK1JAK2JAK3CHEK1 | |
| SCHEMBL17076580 | 0.91 | SYK (0.73) | SYKJAK1JAK2JAK3CHEK1 | |
| SCHEMBL21455068 | 0.91 | SYK (0.73) | SYKJAK1JAK2JAK3CHEK1 | |
| SCHEMBL21455065 | 0.89 | SYK (0.61) | SYKJAK1JAK2JAK3CHEK1 | |
| SCHEMBL21455274 | 0.89 | SYK (0.67) | SYKJAK1JAK2JAK3 | |
| SCHEMBL21455022 | 0.88 | SYK (0.62) | SYKJAK1JAK2JAK3CHEK1 | |
| SCHEMBL21455030 | 0.86 | SYK (0.70) | SYKJAK1JAK2JAK3 | |
| SCHEMBL17076529 | 0.84 | SYK (0.82) | SYKJAK1JAK2JAK3CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10968234-B2 | Compound containing tricyclic heteroaryl group | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2021-04-06 | — | — | US | disclosed |
| US-20200354376-A1 | COMPOUND CONTAINING TRICYCLIC HETEROARYL GROUP | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2020-11-12 | — | — | US | disclosed |
| US-10730887-B2 | Compound containing tricyclic heteroaryl group | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2020-08-04 | — | — | US | disclosed |
| US-20190308993-A1 | COMPOUND CONTAINING TRICYCLIC HETEROARYL GROUP | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2019-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190308993-A1 | COMPOUND CONTAINING TRICYCLIC HETEROARYL GROUP | JAK3, ERBB3, CDK3 | SYK 6/4885JAK1 7/4885JAK2 9/4885 |
| US-10968234-B2 | Compound containing tricyclic heteroaryl group | JAK3, ERBB3, CDK3 | SYK 4/4885JAK1 7/4885JAK2 9/4885 |
| US-20200354376-A1 | COMPOUND CONTAINING TRICYCLIC HETEROARYL GROUP | JAK3, ERBB3, CDK3 | SYK 4/4885JAK1 7/4885JAK2 9/4885 |
| US-10730887-B2 | Compound containing tricyclic heteroaryl group | JAK3, ERBB3, CDK3 | SYK 6/4885JAK1 7/4885JAK2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.